Published in Vaccine Weekly, December 15th, 1997
"The IND was filed on October 29, , in preparation for a planned Phase I clinical trial for the first quarter 1998," said Joseph Marr, MD, ImmuLogic Pharmaceutical Corp. "There are currently no medications approved specifically for treating cocaine addiction. The vaccine technology is a novel approach to address the unmet need in substance abuse treatment."
ImmuLogic previously reported the award of a $2.2 million grant from the National Institute on Drug Abuse...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.